Is anti-cholinesterase therapy of Alzheimer's disease delaying progression? by Giacobini, E.
ABSTRACT. During the last decade, a systemat-
ic effort to develop a pharmacological treatment
for Alzheimer’s disease (AD) resulted in three
drugs being registered for the first time in the US
and Europe. All three compounds are
cholinesterase inhibitors (ChEI). The major ther-
apeutic effect of ChEI on AD patients is to main-
tain cognitive function at a stable level during a 6-
month to 1-year period of treatment, as com-
pared to placebo. Additional drug effects are to
slow down cognitive deterioration and improve be-
havioral and daily living activity. Recent studies
show that in many patients the cognitive stabi-
lization effect can be prolonged up to 24 months.
This long-lasting effect suggests a mechanism of
action other than symptomatic, and directly
cholinergic. In vitro and in vivo studies have con-
sistently demonstrated a link between cholinergic
activation and amyloid precursor protein (APP)
metabolism. Lesions of cholinergic nuclei cause a
rapid increase in cortical APP and cholinergic
synaptic function; the effect of such lesions can be
reversed by ChEI treatment. A reduction in cholin-
ergic neurotransmission, experimental or patho-
logical, leads to amyloidogenic metabolism and
contributes to the development of neuropatholo-
gy and cognitive dysfunction. To explain the long-
term effect of ChEI, for which evidence is available
on an experimental as well as clinical level, a
mechanism based on beta-amyloid metabolism is
postulated. The question whether cholinergic sta-
bilization implies simply slowing down progression
of disability or also involves delay of disease pro-
gression is discussed.
(Aging Clin. Exp. Res. 13: 247-254, 2001)
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CHOLINERGIC THERAPY OF
ALZHEIMER’S DISEASE. HOW DID IT
START?
There are presently three possible modalities of
pharmacological treatment of Alzheimer’s disease
(AD) (Fig. 1); the most explored has been the cholin-
ergic approach.
Basic as well as clinical knowledge of the cholinergic
system, its normal function, and dysfunction form
the theoretical base of the therapy of AD with
cholinesterase inhibitors (ChEI) (1). This strategy was
developed considering that: a) cholinergic neurons
and synapses undergo early and selective damage, as
demonstrated by a decrease in acetylcholine (ACh)
synthesis and nicotinic receptor binding (1); b) a
steady-state rise in synaptic ACh levels following
cholinesterase (ChE) inhibition produces a symp-
tomatic short-term cognitive benefit which can be
demonstrated experimentally in animals and humans;
c) because this effect is short-lasting and symptomat-
ic in nature, efficacy of ChEI should not persist beyond
cessation of the central nervous system (CNS)-ACh el-
evation resulting from ChE inhibition; d) based on
these three conditions, one can predict that early, mild-
ly affected patients should respond best to ChEI ther-
apy, while severely impaired patients with extensive
cholinergic dysfunction would not benefit from this
treatment; e) finally, clinical benefits should be limited
to cognitive (memory), non-behavioral symptomatic
improvement (Table 1).
Recent clinical data seem to contradict such as-
sumptions (Table 2). First, neocortical cholinergic
deficits such as decrease in choline-acetyltransferase
(ChAT) and acetylcholinesterase (AChE) enzymatic ac-
tivity, which are characteristic of severely demented pa-
tients, are not clearly apparent in individuals with
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early mild AD (2). Significant cholinergic enzymatic
deficits are not demonstrable until relatively late in the
course of the disease (2). On the other hand, de-
creases in ChAT activity in the frontal and parietal cor-
tex and in the hippocampus correlate to losses of cog-
nitive domain scores (MDRS, Mattis Dementia Rating
Scale and MMSE, Mini Mental State Examination) (3).
The clinical effect of ChEI seen at early and mild
stages of the disease suggests that the cholinergic
system may be hypo-functional, or that parameters
other than enzyme activity levels are impaired.
Demonstrated deficits are: reduced ACh biosynthesis;
decreased storage and impaired release of ACh, and
cholinergic receptor defective either in number (nico-
tinic) or in function (muscarinic) (1).
To support adequate synthesis and hydrolysis of
ACh under non-physiological conditions, choliner-
gic enzymes are in excess concentrations in the brain
(1). This implies that patients at severe stages of the
disease showing extensive cholinergic damage would
constitute a target for cholinergic treatment. Trials de-
signed specifically to investigate indications for asymp-
tomatic early-phase or severe late-phase patients are
in progress. The preliminary data available suggest that
pharmacological interventions can improve cogni-
tive function in the range from very mild and minimally
cognitively impaired AD patients (cases showing
memory impairment only) to severe cases
(MMSE<10). Treatment duration can be extended
to two-three years, which correspond approximately
to one third of the natural history of the disease,
thus raising the question: is such a prolonged effect of
ChEI only symptomatic, or are ChEI disease-modify-
ing drugs? Recent data, which are summarized in
this paper, support the second alternative. The clini-
cal effect seems to be stronger in more advanced
cases; moreover, treatment benefit seems to be more
pronounced and more long-lasting at higher doses.
The clinical effect of ChEI is measurable three-four
weeks following interruption of the treatment (wash-
out period) despite the fact that ChE inhibition is
strongly diminished or no longer present (4). In this
case, new clinical effect can be demonstrated as an im-
provement in ADAS-Cog scores when treatment is re-
sumed after being suspended for several weeks (3-6
weeks). It seems difficult to explain this stabilizing
effect in terms of symptomatic mechanisms (Table 2).
Evidence accumulated from experiments in animals
and neuronal cell lines suggests a different explanation
(5-7).
CLINICAL DATA SUPPORT A STABILIZING
EFFECT OF CHOLINESTERASE INHIBITORS
The benefit of ChEI treatment was previously con-
sidered to be exclusively symptomatic and cognitive.
It has now been demonstrated that improvement in-
volves cognitive as well as behavioral symptoms (8, 9).
The cognitive improvement is significant up to 12
months (Fig. 2), and several clinical studies have
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Table 1 - Basic assumptions for a cholinergic strategy. Are
they correct?
1. Brain cholinergic neurons and synapses are damaged very ear-
ly in the disease process which results in a decreased level of
acetylcholine.
2. Early, mildly-affected patients will benefit maximally from ChEI
treatment.
3. Treatment benefit will be short-term, symptomatic and mainly
cognitive.
4. Drug effect will not persist beyond cessation of ChE inhibition.
ChEI: Cholinesterase Inhibitors; ChE: Cholinesterase.
Table 2 - Evidence that ChEI clinical effect may not only be
symptomatic.
1. Cognitive deterioration progresses more slowly in treated than
in untreated patients. This effect is dose-dependent.
2. The clinical effect may last for several weeks after drug discon-
tinuation while cholinesterase inhibition in CSF is low or even ab-
sent.
3. The clinical effect is seen also in early, mildly affected patients
with little cholinergic impairment.
4. The strongest clinical effect is seen in rapidly progressing patients.
5. Relatively more advanced patients respond better than early mild
cases.
ChEI: Cholinesterase Inhibitors; CSF: Cholinergic Synaptic Function.
TREATMENT OF ALZHEIMER’S DISEASE:
WHICH WAY TO GO?
TWO WAYS TO GO:
ACETYLCHOLINE
BETA-AMYLOID
THE THIRD WAY:
ESTROGENS
ANTI-OXIDANTS
ANTI-INFLAMMATORIES
CHE-INHIBITORS
MUSCARINICS OR NICOTINICS
Beta-and gamma-secretase inhibitors
Beta-sheet breakers
IMMUNIZATION (anti-beta-A-1-42)
Figure 1 - Pharmacological treatment of Alzheimer’s disease pre-
sent approaches.
demonstrated that the drug effect can be seen for as
long as 2 years in many patients (Table 3). This long-
term effect translates into an improved activity of
daily living for the patient, and a reduced emotional
impact for the caregiver, as well as a reduction in care
costs.
The six-month data available for six ChEI suggest
that patients treated with the active compound change
little cognitively from baseline at the beginning of
the trial to the end of the trial (19, 20). Studies that
approximate a randomized-start design suggest that
treatment with ChEI may delay cognitive deterioration
(21). Two-year open-label data from a donepezil trial
reveal a decline in ADAS-Cog from baseline that is
50% lower than the predicted value; untreated patients
progress more rapidly than treated ones, and the
treatment effect seems to be related to the dose (21).
Average annual rate of decline for patients with a high-
er dose of rivastigmine is almost 50% lower (4.5
ADAS-Cog points/year) than that of patients treated
with a lower dose (8.2 ADAS-Cog points/year) (21).
Increasing the dose of rivastigmine reduces the
rate of cognitive decline over a 3-year period, sug-
gesting a reduction in the rate of progression of cog-
nitive deterioration (10, 21). Clinical data also indicate
that rapidly progressing patients show the strongest
drug effect, therefore, both disease stage and dose of
the ChEI seem to play a role in altering the course of
the disease (21).
Stabilization of cognitive deterioration suggests ei-
ther a protective and structural effect, or a long-term
improvement in the cholinergic synaptic function.
The gradual return to the predicted deterioration-
line after drug wash-out also suggests additional non-
cholinergic effects. The long-term clinical effect could
be related either to cholinesterase inhibition through
the active site of the enzyme (5-7), or to non-cholin-
ergic properties through interaction with a site close
to the peripheral anionic binding site of the enzyme
(22).
LONG-TERM STABILIZING EFFECTS OF
CHOLINESTERASE INHIBITORS
Recent data from 12-24 month open trials and one
randomized placebo-control trial suggest that opti-
mization and maintainance of clinical effects for one
year or more is a feasible goal in many patients
(Table 3). Figure 2 reports the effect on the mean
change in ADAS-Cog score of a 12-month treat-
ment with three ChEI presently in clinical use:
donepezil (17), galantamine (18) and rivastigmine
(10). The data at twelve months show either a small or
no difference from the baseline. The results of several
clinical studies (placebo-controlled and open label)
for periods longer than one year (up to 3 years) are re-
E. Giacobini
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Table 3 - Long-term efficacy of five cholinesterase inhibitors in AD patients.
Reference Drug No. of patients Max. treatment Measures Benefit
No. duration/years difference
11,17 Donepezil 1600 2 ADAS-Cog positive****
46 133 4,9 ADAS-Cog, CDR positive
15 431** 1 ADFAC-CDR positive
16 286*** 1 GBS-MMSE positive
12 Tacrine 25 1 MMSE-EEG positive
13 Metrifonate 432* 1 ADAS-Cog, CIBIC+, MMSE positive
10 Rivastigmine 2149 2 ADAS-Cog, MMSE, CIBIC+, GDS, positive
14 Galantamine 44 3 ADAS-Cog positive
18 636 1 ADAS-Cog positive
Bernhardt and Woelk, 2000 (13)*, Winblad et al., 1999 (15)**, and Mohs et al., 1999 (16)*** are prospective, placebo-controlled, double-blind studies.
Total number of patients: 4258. ****Positive indicates statistically significant clinical improvement from baseline.
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Figure 2 - Stabilization effect of 12-month treatment with four
cholinesterase inhibitors. The patients change little cognitively
from baseline during this period (10, 13, 15, 18).
ported in Table 3 (10-18). These data indicate that
benefit differences can be maintained in a number of
patients for up to 12-24 months by five different in-
hibitors (donepezil, tacrine, metrifonate, rivastigmine
and galantamine). In terms of global improvement in
the ADAS-Cog score, this may sum up to a total
15-20 point gain, which represents an 18-24 month
difference in disease history from placebo-treated pa-
tients. How to interpret this improvement? Is it the re-
sult of slowing down the increase of disability, or is it
an expression of delaying progression of the dis-
ease? This question is similar to that asked in reference
to the effect of MAO-B inhibitors such as selegyline
with regard to Parkinson disease.
BASIC RESEARCH DATA SUPPORTING
NON-SYMPTOMATIC EFFECT OF
CHOLINESTERASE INHIBITORS
The amyloid precursor protein (APP) pathway that
generates beta-amyloid (beta-A) is regulated by the se-
quential action of three enzymes (alpha, beta and
gamma secretases). Alpha secretase cleaves APP
within the beta-A sequence, and releases soluble N-ter-
minal non-aggregating fragments (sAPP) (Fig. 3). Nu-
merous studies have shown that the stimulation of
sAPP release is associated with reduced formation of
amyloidogenic peptides. Muscarinic-agonist-induced
sAPP secretion through activation by carbachol of m1
and m3 (but not m2 and m4) receptor subtypes in-
creases sAPP release in human embryonic cell lines
(23). Activation of the pathway that cleaves APP de-
creases the release of beta-A fragments, and may
slow down amyloid formation in the brain. On the ba-
sis of the results obtained in superfused rat cortex slices
demonstrating an increased release of sAPP in re-
sponse to muscarinic stimulation, we proposed an ef-
fect of ChEI on sAPP secretion acting through the
same pathway (5) (Fig. 3).
Racchi et al. (6) using neuroblastoma cells, and
Pakaski et al. (7) using primary cultures of rat basal
forebrain neurons have shown that short-term treat-
ment with reversible and irreversible ChEI such as am-
benomium, and metrifonate or its metabolite DDVP,
increases sAPP release into the conditioned media,
and elevates protein kinase C (PKC) levels. These
studies demonstrated that this effect on APP is con-
sistent with AChE inhibition, and with indirect mus-
carinic-mediated cholinergic stimulation. In addition,
short-term or long-term stimulation does not result in
changes in APP mRNA expression either in cortical
slices or neuroblastoma cells (6, 20), nor in a down-
regulation of the response to cholinergic stimulation of
muscarinic receptors (6). These results suggest that
ChEI promote the non-amyloidogenic route of APP
processing through a stimulation of alpha-secretase ac-
tivity mediated by PKC (Fig. 3).
This demonstrated feature of ChEI and of mus-
carinic agonists, and their ability to enhance the re-
lease of non-amyloidogenic soluble derivatives of
APP in vitro and in vivo suggests a slowing down in
the formation of amyloidogenic compounds in the
brain (1).
EFFECT OF CHOLINERGIC STIMULATION
ON BETA-A BRAIN METABOLISM?
Selective muscarinic (m1) direct activation of al-
pha-secretase activity accelerates APP processing,
and consequently decreases the generation of beta-A
peptides in cellular model systems (6, 7, 23). A re-
duction in both total beta-A and beta-1-42 peptide lev-
els in the cholinergic synaptic function (CSF) is seen in
AD patients treated for 4 weeks with either AF102B,
Anti-cholinesterase therapy
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Figure 3 - Secretion of sAPP can be increased in the brain by di-
rect stimulation of m1 muscarinic receptors, or indirectly
through cholinesterase inhibition producing an increase in
acetylcholine and subsequent protein phosphorylation (PKC).
This effect might concomitantly decrease the production of
potentially amyloidogenic Beta-A peptides and slow down pro-
gression of the disease.
ACh: Acetylcholine; PKC: Protein Kinase C; APP: Amyloid
Precursor Protein; -Secr: Alfa-Secretases; -A: beta-Amlyoid; M1:
m1 muscarinic receptors.
or talsaclidine in placebo-controlled trials (24). Both
drugs are selective m1 agonists. The decrease in total
CSF beta-A is in the range of 10-40% in 80% of pa-
tients (24). No changes are seen in either total tau or
phosphorylated tau CSF levels. Levels of total beta-A
do not change following treatment with the ChEI
physostigmine, or with the anti-inflammatory drug
hydroxychloroquine. It is interesting to note that
physostigmine, in contrast to metrifonate, does not
show any effect on sAPP secretion in cell lines (25). In
rat cortical slices, the physostigmine effect is dose-de-
pendent (5). Tacrine, on the other hand, was shown
to increase sAPP release and decrease levels of beta-
A, beta-1-40 and beta-1-42 in both cell lines and
cortical slices (25, 26).
Lahiri et al. (25) demonstrated that levels of soluble
beta-1-42 were reduced by 20-25% when human
neuroblastoma cells were treated with either 3,4 di-
aminopyridine, metrifonate or tacrine, but were un-
changed with physostigmine. In these experiments, lev-
els of shorter beta-A species were found to be 10-fold
higher than longer and potentially amyloidogenic be-
ta-1-42 species (25). Metrifonate treatment resulted in
the lowest percent accumulation of the beta-1-42
species relative to the total secreted into the conditioned
media than any other drug tested. It was also found that
the effects of ChEI on sAPP release do not depend on
their selectivity for either AChE or BuChE.
On the basis of the results obtained in vitro and in
vivo, ChEI can be classified into two groups: the first
group with little or no effect on APP processing as ex-
emplified by physostigmine, and the second group rep-
resented by drugs such as tacrine and metrifonate that
increase APP release and decrease beta-A levels.
The fact that anti-amyloid properties are not common
to all ChEI poses the question of optimization of
cholinergic properties combined with anti-amyloid
effects as a challenge for future drug development (1).
ChE BRAIN INHIBITION AND CLINICAL
EFFECT: A CRITICAL RELATION
The cognitive effect (ADAS-Cog) seen with most
ChEI becomes statistically significant after 2-3 weeks
of treatment (Fig. 2). This delay may be due to at-
tenuation of the placebo effect. In most patients,
some decrease in the clinical effect is observed fol-
lowing a period of 30-36 weeks of treatment. Does
this decrease depend on progressive patient deterio-
ration, or on other factors such as lower clinical effi-
cacy of ChEI medication? How is the long-term clin-
ical effect maintained if enzyme inhibition is pro-
gressively decreasing?
The data suggest that tolerance to repeated doses
of ChEI, combined with patient deterioration, may
contribute to attenuate the clinical effect of the drug.
There is a vast literature addressing the phenomenon
of tolerance to both single and repeated doses of
ChEI (27). Adaptation due to decreased effect of
ChEI is supported by behavioral as well as toxicolog-
ical studies (27). Tolerance to repeated doses of ChEI
might be explained by two mechanisms (27). First, a
reduction in sensitivity due to ACh elevation causes a
decrease in the number (down-regulation) of mus-
carinic and/or nicotinic receptors. Alzheimer patients
at advanced disease stages show a deficit in synthesis
and levels of Ach, and a decrease in nicotinic (but not
muscarinic) receptor number (28).
A second, more likely explanation, is the induction of
new enzyme synthesis by increased AChE gene ex-
pression at nerve terminals (29). Direct stimulation of m1
muscarinic receptors or ACh itself may be the signal for
increased gene expression. Von der Kammer et al.
(29) demonstrated activation of m1 increased tran-
scription from Egr-dependent promoters, including the
AChE promoter. This effect is reflected by an increased
level of AChE activity (not an inhibition!) in the CSF of
long-term treated patients (1, 10, 30-33) (Table 4).
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Table 4 - Effect of ChEI on CSF and RBC AChE activity (1).
Ref. No. Drug Route of administration (dose) AChE activity (percent) Time
CSF RB
1 physostigmine icv (1 μg) 30 100 5 minutes
1 physostigmine icv (8 μg) 15 100 5 minutes
10 rivastigmine oral (3 mg) 70 90 2 hours
30 rivastigmine oral (12 mg) 60 21** 12 months
31 tacrine oral (80-160 mg) 150 75 12 months
32 metrifonate oral (2.9 mg/kg w.) 40-100 33 6 months
33 metrifonate oral (2.9 mg/kg w.) 92 35 24 months*
* Open label (33), ** ChE activity in plasma (30).
CSF: Cholinergic Synaptic Function; RBC: Red Blood Cells; AChE: Acetylcholinesterase; ChE: Cholinesterase; icv: intracerebral ventricular.
Stimulation of AChE release from CNS neurons in-
to the CSF by the action of ChEI has been invoked by
Bareggi and Giacobini (34). Increased AChE activity
in the CSF was demonstrated by Mattio et al. (35) in
dogs chronically administered high doses of physostig-
mine intraventricularly. An example of upregulation of
AChE activity is seen in the CSF of tacrine-treated pa-
tients (80-160 mg for 12 months), as reported by
Nordberg et al. (31) (Table 4). In this study, no change
was observed in AChE inhibition in RBC, while a
50% increase (sic) in AChE (but not BuChE) activity
was seen in the CSF. Other observations indicate
that an upregulated synthesis of both AChE and
BuChE may occur in dogs and rats treated with vari-
ous types of ChEI (1). Metrifonate, an organophos-
phate ChEI, does not produce AChE upregulation in
the brain or RBC of rats treated for 12 weeks (36). In
AD patients, RBC AChE inhibition is the same at 2,
8 and 12 weeks following oral administration (0.65-
2.0 mg/kg/day) of metrifonate (33). This is in agree-
ment with the data on CSF following rivastigmine
treatment, but in contrast with the effect of tacrine on
CSF ChE (30) (Table 4).
In conclusion, there seems to be a difference in the
production of tolerance and enzymatic induction
among different compounds. It is surprising that in cer-
tain cases clinical efficacy can be maintained despite
low enzymatic effect, implying mechanisms other
than ChE inhibition.
HOW TO EXPLAIN A POSSIBLE DISEASE-
MODIFYING EFFECT OF CHOLINESTERASE
INHIBITORS?
Table 5 summarizes the special relationship be-
tween AChE and beta-amyloid in the brain of AD pa-
tients (1). Accordingly, AChE, which is present in a
glycosylated form associated with the amyloid core of
neuritic plaques (37), is stimulated in its synthesis by
beta-amyloid. AChE stimulates beta-amyloid accu-
mulation in or near to the plaque (22, 40) (Fig. 4).
One first explanation for a long-term neuropro-
tective effect of ChEI is an interaction of the beta-A cy-
cle with ChEI, promoting the release of soluble forms
of beta-APP, and the reduction of amyloidogenic
forms. Such a mechanism implies the regulation of al-
pha secretase activity as the common final effector of
PKC-dependent modulation of APP metabolism act-
ing through a muscarinic m1 receptor, as supported by
experimental evidence (5-7, 20, 23). Secretion of
APP soluble forms related to ChE inhibition has been
demonstrated in vitro and in vivo in the CSF of
NBM lesioned rats (rivastigmine and phenserine) (44),
neuroblastoma cells for metrifonate (6), rat cortex
slices (metrifonate) (5), rat basal forebrain cell cul-
tures (metrifonate and ambenomium) (7), and in hu-
man neuroblastoma cells for several ChEI (25, 45).
A second hypothesis is based on the data showing
that the AChE molecule may interact with beta-amy-
loid through a hydrophobic site close to the peripheral
anionic binding site (PAS), promoting amyloid fibril for-
mation (22). In addition, AChE is incorporated into se-
nile plaques in vitro by forming macromolecular
complexes with the growing beta-amyloid fibrils (44).
AChEI binding to PAS may reduce this formation.
Both hypotheses need clinical confirmation utilizing
CSF markers to monitor brain beta-amyloid levels
and metabolism in patients treated with ChEI for a
long term. Studies are in progress to verify such an ef-
fect in patients.
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Table 5 - Acetylcholinesterase-beta-amyloid relationship in AD
brain.
ACETYLCHOLINESTERASE:
1. Is associated with the amyloid core of neuritic plaques (37).
The hydrophobic site of aggregation is distinct from the enzy-
matic active site (38).
2. Is abnormally glycosylated (39, 40) and its expression is stimu-
lated by beta-amyloid (23, 40).
3. Is increased within and around the amyloid plaques (37) and pro-
motes aggregation of amyloid beta-peptide fragments (41).
4. Is increased in the brain of transgenic mice expressing the c-ter-
minal fragment of the beta-amyloid precursor protein (42).
5. Nucleus basalis lesions increase synthesis of beta-amyloid (43).
AChE
APP**
PROCESSINGAChE I
***
+Ca++ Inestrosa et al., 1996
Suh et al., 1996
Mori et al., 1995
Small et al., 1998
AChE- AMYLOID*
COMPLEX
*
**
***
****
AChE****
EXPRESSION
GLYCOSILATION
Figure 4 - Proposed beta-amyloid cycle: AChE co-localizes with
beta-amyloid and accelerates beta-amyloid formation and de-
position in AD brain. Beta-amyloid increases AChE in the
brain. Inhibition of AChE activity inhibiting APP release reduces
beta-amyloid deposition. This mechanism could contribute to the
patient long-term cognitive stabilization seen during AChEI
treatment.
AChE: Acetylcholinesterase; APP: Amyloid Precursor Protein.
The longest clinical study on the effect of a ChEI
was performed as an extension trial lasting almost 5
years. The results demonstrate treatment benefits on
cognition and global function in patients progressing
from mild to moderate AD, and from moderate to se-
vere AD over a period of 4, 9 years (46). The mean
annual rate of decline in ADAS-Cog and CDR (Clin-
ical Dementia Rating) of patients receiving the ChEI
was significantly less over the first through the third
year of treatment than might be predicted had this co-
hort of patients not been treated (46). This long-
term efficacy supports the concept of a disease-de-
laying effect of this class of drugs.
CONCLUSIONS
In vitro as well as in vivo studies have consistent-
ly demonstrated a link between cholinergic activa-
tion and APP metabolism. A lesion of the cholinergic
nuclei (nucleus basalis Meynert) causes a rapid in-
crease in APP in the neocortex and CSF of rats (43).
The effect of such lesions can be reversed by treatment
with ChEI (44). A reduction in cholinergic neuro-
transmission, experimental or pathological, leads to
amyloidogenic metabolism in the brain, and con-
tributes to the neuropathology and cognitive dys-
function. Cholinesterase inhibitors may interact with
both mechanisms, stabilizing the patient. This inter-
pretation establishes a relationship between the effects
of cholinergic drugs with a muscarinic mechanism
of action, such as ChEI, and muscarinic agonists with
treatments specifically targeted to decrease the beta-
amyloid burden in the brain (Fig. 1).
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